GH RESEARCH PLC DL-025 (1KA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GH RESEARCH PLC DL-025 (1KA) has a cash flow conversion efficiency ratio of -0.042x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-15.02 Million ≈ $-17.56 Million USD) by net assets (€359.49 Million ≈ $420.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GH RESEARCH PLC DL-025 stock valuation for the company's overall valuation and market capitalisation.
GH RESEARCH PLC DL-025 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how GH RESEARCH PLC DL-025's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of GH RESEARCH PLC DL-025 for real-time trading data and today's change.
GH RESEARCH PLC DL-025 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GH RESEARCH PLC DL-025 ranked by their cash flow conversion efficiency. Review 1KA free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VIA Technologies Inc
TW:2388
|
0.028x |
|
Arcelik AS
IS:ARCLK
|
0.055x |
|
Jiangsu Evergreen New Material Technology Inc. Co. A
SHG:603125
|
N/A |
|
Grupo Televisa S.A.B
MX:TLEVISACPO
|
0.100x |
|
PROG Holdings Inc
NYSE:PRG
|
0.222x |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
0.055x |
|
Afry AB
ST:AFRY
|
0.065x |
|
Canfor Corporation
TO:CFP
|
0.079x |
Annual Cash Flow Conversion Efficiency for GH RESEARCH PLC DL-025 (2021–2025)
The table below shows the annual cash flow conversion efficiency of GH RESEARCH PLC DL-025 from 2021 to 2025. Also see GH RESEARCH PLC DL-025 balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €279.70 Million ≈ $327.00 Million |
€-43.55 Million ≈ $-50.92 Million |
-0.156x | +34.10% |
| 2024-12-31 | €178.95 Million ≈ $209.21 Million |
€-42.28 Million ≈ $-49.44 Million |
-0.236x | -55.21% |
| 2023-12-31 | €218.97 Million ≈ $256.00 Million |
€-33.34 Million ≈ $-38.97 Million |
-0.152x | -45.17% |
| 2022-12-31 | €249.82 Million ≈ $292.06 Million |
€-26.20 Million ≈ $-30.63 Million |
-0.105x | -90.20% |
| 2021-12-31 | €277.18 Million ≈ $324.05 Million |
€-15.28 Million ≈ $-17.87 Million |
-0.055x | -- |
About GH RESEARCH PLC DL-025
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more